Giant cell arteritis: proven and debatable aspects of treatment

Authors

DOI:

https://doi.org/10.22141/2224-1507.10.1.2020.199720

Keywords:

giant cell arteritis, drug therapy, complications, treatment outcome, standards, review

Abstract

Giant cell arteritis is the most common systemic vasculitis in adults and especially in older people. Its development and treatment is often associated with comorbidities, relapses and va­rious complications. The paper represents an analytical review, systema­tic generalization and discussion of evidence on modern strategies, main risks, medicines and outcomes of the treatment of patients with giant cell arteritis. We studied specialized literature data published in English, Russian and German, found by electronic and manual search, checked for indexing in the main computer databa­ses of evidence-based medicine (Cochrane Library and Medline) and selec­ted without time limiting. Special attention is paid to prevention of early and severe complications and adverse effects of therapy — eye, cardiovascular, cerebrovascular and infectious diseases, diabetes, osteoporosis, fractures and malignancies. Best practice and the results of the introduction of an accelerated approach to management of a patient with suspected giant cell arteritis in primary healthcare setting are described, as well as current evidence base and prospects for early diagnosis and use of glucocorticoids and adjuvant immunosuppressive and biologic therapy with a focus on methotrexate and tocilizumab. Main principles, recommendations and evidence base of the 2020 British Society for Rheumatology guidelines on diagnosis and treatment of this vasculitis are represented and discussed.

Downloads

Download data is not yet available.

References

De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol. 2015;42(1):119–125. https://doi.org/10.3899/jrheum.140318.

Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1–e23. https://doi.org/10.1093/rheumatology/kez672.

Pfeil A, Oelzner P, Hellmann P. The Treatment of Giant Cell Arteritis in Different Clinical Settings. Front Immunol. 2019;9:3129. https://doi.org/10.3389/fimmu.2018.03129.

Barraclough K, Mallen CD, Helliwell T, Hider SL, Dasgupta B. Diagnosis and management of giant cell arteritis. Br J Gen Pract. 2012;62(599):329–330. https://doi.org/10.3399/bjgp12x649313.

Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50–57. https://doi.org/10.1056/nejmcp1214825.

Ninan J, Lester S, Hill C. Giant cell arteritis. Best Pract Res Clin Rheumatol. 2016;30(1):169–188. https://doi.org/10.1016/j.berh.2016.05.001.

Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM. Giant Cell Arteritis: From Pathogenesis to Therapeutic Management. Curr Treatm Opt Rheumatol. 2016;2(2):126–137. https://doi.org/10.1007/s40674-016-0043-x.

Lisitsyna TA, Veltishchev DY, Lila AM, Nasonov EL. Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders. Rheumatology Science and Practice. 2019;57(3):318–327. https://doi.org/10.14412/1995-4484-2019-318-327. (in Russian).

Brennan DN, Ungprasert P, Warrington KJ, Koster MJ. Smoking as a risk factor for giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(3):529–537. https://doi.org/10.1016/j.semarthrit.2018.07.001.

Svensjö S, Björck M, Gürtelschmid M, Djavani Gidlund K, Hellberg A, Wanhainen A. Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation. 2011;124(10):1118–1123. https://doi.org/10.1161/circulationaha.111.030379.

Brekke LK, Diamantopoulos AP, Fevang BT, Aβmus J, Esperø E, Gjesdal CG. Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study. Arthritis Res Ther. 2017;19(1):278. https://doi.org/10.1186/s13075-017-1479-6.

Netiazhenko VZ, Puzanova OG. Giant cell arteritis: epidemiology, diagnosis, prognosis. Pain, joints, spine. 2019;9(2):90–107. https://doi.org/10.22141/2224-1507.9.2.2019.172121. (in Russian).

Smith JH, Swanson JW. Giant cell arteritis. Headache. 2014;54(8):1273–1289. https://doi.org/10.1111/head.12425.

Patil P, Williams M, Maw WW, et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33(2 Suppl 89).

Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217(4):239–259. https://doi.org/10.1159/000070631.

Baig IF, Pascoe AR, Kini A, Lee AG. Giant cell arteritis: early diagnosis is key. Eye Brain. 2019;11:1–12. https://doi.org/10.2147/eb.s170388.

Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–1597. https://doi.org/10.1093/rheumatology/keq039a.

Prior JA, Ranjbar H, Belcher J, et al. Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis. BMC Med. 2017;15(1):120. https://doi.org/10.1186/s12916-017-0871-z.

Chen JJ, Leavitt JA, Fang C, Crowson CS, Matteson EL, Warrington KJ. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology. 2016;123(9):1999–2003. https://doi.org/10.1016/j.ophtha.2016.05.008.

Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?. Rheumatology (Oxford). 2016;55(1):66–70. https://doi.org/10.1093/rheumatology/kev289.

Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110(6):1204–1215. https://doi.org/10.1016/s0161-6420(03)00228-8.

Salehi-Abari I. 2016 ACR Revised Criteria For Early Diagnosis Of Giant Cell (Temporal) Arteritis. Autoimmune Dis Ther Approaches. 2016;3(1). http://doi.org/10.14437/2378-6337-3-119.

El-Dairi MA, Chang L, Proia AD, Cummings TJ, Stinnett SS, Bhatti MT. Diagnostic Algorithm for Patients With Suspected Giant Cell Arteritis. J Neuroophthalmol. 2015;35(3):246–253. https://doi.org/10.1097/wno.0000000000000234.

Bunchuk NV. Revmaticheskie zabolevaniia pozhilykh [Rheumatic diseases of the elderly]. Moscow: MEDpress-inform; 2010. 272p. (in Russian).

Kumar B, Toney DE, Alikhan M, Lohr KM. Giant cell arteritis presenting as depressed mood and headache in an elderly patient. J Clin Rheumatol. 2013;19(7):405–406. https://doi.org/10.1097/rhu.0b013e3182a701e8.

Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636–643. https://doi.org/10.1136/annrheumdis-2017-212649.

Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford). 2018;57(suppl_2):ii32–ii42. https://doi.org/10.1093/rheumatology/kex424.

Bienvenu B, Ly KH, Lambert M, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016;37(3):154–165. https://doi.org/10.1016/j.revmed.2015.12.015.

Stone JR, Bruneval P, Angelini A, et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol. 2015;24(5):267–278. https://doi.org/10.1016/j.carpath.2015.05.001.

Hocevar A, Rotar Z, Jese R, et al. Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study. Medicine (Baltimore). 2016;95(14):e3210. https://doi.org/10.1097/md.0000000000003210.

Liozon E, de Boysson H, Dalmay F, et al. Development of Giant Cell Arteritis after Treating Polymyalgia or Peripheral Arthritis: A Retrospective Case-control Study. J Rheumatol. 2018;45(5):678–685. https://doi.org/10.3899/jrheum.170455.

Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken). 2015;67(3):390–395. https://doi.org/10.1002/acr.22429.

Mohammad AJ, Englund M, Turesson C, Tomasson G, Merkel PA. Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. J Rheumatol. 2017;44(1):84–90. https://doi.org/10.3899/jrheum.160249.

Pujades-Rodriguez M, Duyx B, Thomas SL, Stogiannis D, Smeeth L, Hemingway H. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart. 2016;102(5):383–389. https://doi.org/10.1136/heartjnl-2015-308514.

Chazal T, Lhote R, Rey G, et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmun Rev. 2018;17(12):1219–1224. https://doi.org/10.1016/j.autrev.2018.06.012.

Brekke LK, Fevang BS, Diamantopoulos AP, Assmus J, Esperø E, Gjesdal CG. Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study. Arthritis Res Ther. 2019;21(1):154. https://doi.org/10.1186/s13075-019-1945-4.

Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29(10):2143–2147.

Ungprasert P, Sanguankeo A, Upala S, Knight EL. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(3):366–370. https://doi.org/10.1016/j.semarthrit.2014.06.004.

Bellan M, Boggio E, Sola D, et al. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med. 2017;12(5):621–627. https://doi.org/10.1007/s11739-017-1626-8.

Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018;38(4):569–577. https://doi.org/10.1007/s00296-017-3874-3.

Wilson JC, Sarsour K, Collinson N, et al. Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. Semin Arthritis Rheum. 2017;46(5):650–656. https://doi.org/10.1016/j.semarthrit.2016.10.001.

Wilson JC, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Semin Arthritis Rheum. 2017;46(6):819–827. https://doi.org/10.1016/j.semarthrit.2016.11.006.

Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: a cohort study. Arthritis Care Res (Hoboken). 2012;64(4):581–588. https://doi.org/10.1002/acr.21569.

Udayakumar PD, Chandran AK, Crowson CS, Warrington KJ, Matteson EL. Hospitalized infections in giant cell arteritis: a population-based retrospective cohort study. J Rheumatol. 2014;41(12):2447–2451. https://doi.org/10.3899/jrheum.140124.

Schmidt J, Smail A, Roche B, et al. Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study. Arthritis Rheumatol. 2016;68(6):1477–1482. https://doi.org/10.1002/art.39596.

Recommendation 00789. Temporal (giant cell) arteritis. Evidence based recommendations. Developed by DUODECIM Medical Publications, Ltd. Available from: https://guidelines.moz.gov.ua/documents/3570. Accessed: 14.02.2020. (in Ukrainian).

Paskins Z, Whittle R, Sultan AA, et al. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med. 2018;16(1):4. https://doi.org/10.1186/s12916-017-0987-1.

Reiter S, Winocur E, Goldsmith C, Emodi-Perlman A, Gorsky M. Giant cell arteritis misdiagnosed as temporomandibular disorder: a case report and review of the literature. J Orofac Pain. 2009;23(4):360–365.

Makarenkо ЕV. Giant cell arteritis. Part I. Vestnik VGMU. 2017;16(5):21–30. https://doi.org/10.22263/2312-4156.2017.5.21. (in Russian).

Beketova TV, Satybaldyev AM, Denisov LN. International guidelines for the management of giant cell arteritis and polymyalgia rheumatica: The 2015 results. Rheumatology Science and Practice. 2016;54(4):390–394. https://doi.org/10.14412/1995-4484-2016-390-394. (in Russian).

Makarenkо EV. Giant cell arteritis. Part II. Vestnik VGMU. 2017;16(5):31–39. https://doi.org/10.22263/2312-4156.2017.5.21. (in Russian).

Luqmani R, Lee E, Singh S, et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016;20(90):1–238. https://doi.org/10.3310/hta20900.

Smetana GW, Shmerling RH. Does this patient have temporal arteritis?. JAMA. 2002;287(1):92–101. https://doi.org/10.1001/jama.287.1.92.

Liozon E, Dalmay F, Lalloue F, et al. Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients. J Rheumatol. 2016;43(7):1393–1399. https://doi.org/10.3899/jrheum.151135.

Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41(1):26–32. https://doi.org/10.1002/1529-0131(199801)41:1%3C26::aid-art4%3E3.0.co;2-0.

Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009;48(3):250–253. https://doi.org/10.1093/rheumatology/ken465.

Gonzalez-Gay MA, Piñeiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004;83(6):342–347. https://doi.org/10.1097/01.md.0000145369.25558.b5.

Yates M, MacGregor AJ, Robson J, et al. The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology (Oxford). 2017;56(4):524–528. https://doi.org/10.1093/rheumatology/kew397.

de Boysson H, Daumas A, Vautier M, et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun Rev. 2018;17(4):391–398. https://doi.org/10.1016/j.autrev.2017.11.029.

Muratore F, Kermani TA, Crowson CS, et al. Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?. Arthritis Care Res (Hoboken). 2018;70(9):1406–1411. https://doi.org/10.1002/acr.23498.

Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3522–3531. https://doi.org/10.1002/art.11353.

Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83(6):335–341. https://doi.org/10.1097/01.md.0000145366.40805.f8.

Gonzalez-Gay MA, Garcia-Porrua C, Gonzalez-Juanatey C, Miranda-Filloy JA, Blanco R, Llorca J. Biopsy-proven giant cell arteritis patients with coronary artery disease have increased risk of aortic aneurysmal disease and arterial thrombosis. Clin Exp Rheumatol. 2013;31(1 Suppl 75):S94.

Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis. 2015;74(1):129–135. https://doi.org/10.1136/annrheumdis-2013-204113.

Hachulla E, Boivin V, Pasturel-Michon U, et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol. 2001;19(2):171–176.

Nesher G, Nesher R, Mates M, Sonnenblick M, Breuer GS. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S30–S34.

Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194–201. https://doi.org/10.1097/md.0000000000000033.

Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54(3):463–470. https://doi.org/10.1093/rheumatology/keu329.

Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952–957. https://doi.org/10.1136/annrheumdis-2015-208916.

Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–1913. https://doi.org/10.1136/annrheumdis-2013-203249.

Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317–328. https://doi.org/10.1056/nejmoa1613849.

Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis [published correction appears in Arthritis Care Res (Hoboken). 2012 Mar;64(3):464]. Arthritis Care Res (Hoboken). 2010;62(11):1515–1526. https://doi.org/10.1002/acr.20295.

van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414–422. https://doi.org/10.1136/ard.2010.137216.

Puzanovа ОG. Nutrition as both risk factor and intervention in rheumatic diseases. Pain, joints, spine. 2019;9(3):149–169. https://doi.org/10.22141/2224-1507.9.3.2019.178640. (in Russian).

Rausch Osthoff AK, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(9):1251–1260. https://doi.org/10.1136/annrheumdis-2018-213585.

Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484–1491.

Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309–1318. https://doi.org/10.1002/art.10262.

Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–3318. https://doi.org/10.1002/art.22163.

Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–1927. https://doi.org/10.1016/s0140-6736(16)00560-2.

Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306–2309. https://doi.org/10.1093/rheumatology/ket445.

Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989;48(8):658–661. https://doi.org/10.1136/ard.48.8.658.

Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82(5):613–618. https://doi.org/10.7326/0003-4819-82-5-613.

Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–114. https://doi.org/10.7326/0003-4819-134-2-200101160-00010.

Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.

Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–2797. https://doi.org/10.1002/art.22754.

Müller-Ladner U, Rau R. Methotrexat bei Autoimmunerkrankungen - Moderne Therapiekonzepte in der Rheumatologie, Dermatologie und Gastroenterologie [Methotrexate for autoimmune diseases - modern therapy concepts in rheumatology, dermatology and gastroenterology]. Bremen: UNI-MED; 2016. 120p. (in German).

Yates M, Loke YK, Watts RA, MacGregor AJ. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol. 2014;33(2):227–236. https://doi.org/10.1007/s10067-013-2384-2.

De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136–138. https://doi.org/10.1136/ard.45.2.136.

Liozon F, Vidal E, Barrier J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity?. Clin Exp Rheumatol. 1993;11(6):694–695.

Schaufelberger C, Möllby H, Uddhammar A, Bratt J, Nordborg E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol. 2006;35(4):327–329. https://doi.org/10.1080/03009740500474537.

Beketova TV, Ushakovа МA, Nikishinа NY, et al. Experience with tocilizumab, an interleukin 6 inhibitor, used for the treatment of giant cell arteritis with severe comorbidity. Rheumatology Science and Practice. 2018;56(2):228–234. https://doi.org/10.14412/1995-4484-2018-228-234. (in Russian).

Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol. 2017;69(4):837–845. https://doi.org/10.1002/art.40044.

Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–630. https://doi.org/10.7326/0003-4819-146-9-200705010-00004.

Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074–2081. https://doi.org/10.1136/annrheumdis-2013-203586.

Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625–630. https://doi.org/10.1136/ard.2007.082115.

Mollan SP, Sharrack N, Burdon MA, Denniston AK. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. 2014;(8):CD010453. https://doi.org/10.1002/14651858.cd010453.pub2.

Downloads

Published

2021-09-24

How to Cite

Lyzikov А., Puzanova О., & Lyzikov А. (2021). Giant cell arteritis: proven and debatable aspects of treatment. PAIN, JOINTS, SPINE, 10(1), 9–30. https://doi.org/10.22141/2224-1507.10.1.2020.199720

Issue

Section

Reviews